Loading
A phase 3 trial of cisplatin and pemetrexed in lung cancer, run by Shanghai JMT-Bio Inc., not yet recruiting.
JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations is a phase 3, randomised interventional study registered as NCT06380348 by Shanghai JMT-Bio Inc., with a registry enrolment figure of 398 participants, started 2024-04-26 and due to reach its primary completion in 2027-03-26. Interventions recorded: JMT101 Injection; Osimertinib tablet; Cisplatin injection; Pemetrexed injection. Conditions listed: Local Advanced or Metastatic NSCLC. Primary outcome: Progression Free Survival (PFS) as assessed by Independent Review Center (IRC) per RECIST 1.1. Lung eligibility wording from the registry: "Histologically or cytologically confirmed diagnosis of NSCLC, locally advanced (Stage IIIB and IIIC according to the 8th edition of the IASLC TNM staging criteria) or metastatic (Stage IV), not suitable for curative therapy". No results are recorded here; the registry entry is the source.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Cisplatin and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Cisplatin and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Cisplatin and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Cisplatin and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents and the tag lung-deep-dive.